Article Sidebar
Published:
Feb 16, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Synthesis of 2-[2,3-dihydro-1,4-benzodioxin-6-yl(phenylsulfonyl)amino]-N-(un/substituted-phenyl)acetamides as anti-diabetic agents
Abstract
Purpose: To synthesize a series of new 2-[2,3-dihydro-1,4-benzodioxin-6-yl(phenylsulfonyl)amino]-N-(un/substituted-phenyl) acetamides, and evaluate their anti-diabetic potentials.
Methods: Synthesis of the parent compound N-(2,3-dihydro-1,4-benzodioxin-6-yl) benzenesulfonamide (3) was carried out by reacting 2,3-dihydro-1,4-benzodioxin-6-amine (1) with benzenesulfonylchloride (2) in aqueous basic medium under definite pH controls. After that 3 was further treated with various 2-bromo-N-(un/substituted-phenyl)acetamides (6a-l) to yield new compounds (7a-l) in polar aprotic solvent, DMF (dimethylformamide), using LiH as activator. The proposed structures of the synthesized compounds were confirmed using proton-nuclear magnetic resonance (1H-NMR) and infra-red spectroscopy (IR), and CHN analysis. Their anti-diabetic potential was evaluated by α-glucosidase enzyme inhibitory studies.
Results: All the new compounds demonstrated weak (7a-h, 7j and 7l) to moderate (7i and 7k) inhibitory activities against α-glucosidase enzyme. IC50 (50 % inhibition concentration) values for 7i and 7k were 86.31±0.11 μM and 81.12±0.13 μM, respectively relative to acarbose (reference standard) with IC50 of 37.38±0.12 μM.
Conclusion: All the synthesized compounds have weak to moderate activity against α-glucosidase enzyme. These compounds can thus be considered as possible therapeutic entrants for type-2 diabetes.
